NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Sunshine Biopharma Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Sunshine Biopharma is a pharmaceutical company offering and researching medicines across multiple therapeutic areas, including oncology and antivirals. Through its subsidiary Nora Pharma, it markets generic prescription drugs in Canada, while Sunshine Biopharma Canada develops and sells over-the-counter supplements. The company also conducts proprietary drug development programs for liver cancer and coronavirus treatments.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Sunshine Biopharma Inc stock.
No reliable verdict: intrinsic value $24.08 per share, market price $2.54 (as of 2026-11-17).
Its current assets minus all its liabilities would put the shares at $24.08: 9 times the price of $2.54. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
All 82 Drug Manufacturers - Specialty & Generic stocks
We do not publish a verdict on SBFM. Its current assets minus all its liabilities would put the shares at $24.08: 9 times the price of $2.54. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.
We do not publish one (as of the 2026-11-17 close). Its current assets minus all its liabilities would put the shares at $24.08: 9 times the price of $2.54. A gap that size says more about a model than about the market. It usually means heavy debt, where a small error in the value of the business becomes a large one in the value of the shares, or a business our method does not describe. We do not publish a verdict on this one.